These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

133 related items for PubMed ID: 8707444

  • 1. The specific type IV phosphodiesterase inhibitor rolipram combined with adenosine reduces tumor necrosis factor-alpha-primed neutrophil oxidative activity.
    Sullivan GW, Carper HT, Mandell GL.
    Int J Immunopharmacol; 1995 Oct; 17(10):793-803. PubMed ID: 8707444
    [Abstract] [Full Text] [Related]

  • 2. Adenosine modulation of tumor necrosis factor-alpha-induced neutrophil activation.
    Barnes CR, Mandell GL, Carper HT, Luong S, Sullivan GW.
    Biochem Pharmacol; 1995 Nov 27; 50(11):1851-7. PubMed ID: 8615864
    [Abstract] [Full Text] [Related]

  • 3. Methylxanthines with adenosine alter TNF alpha-primed PMN activation.
    Sullivan GW, Luong LS, Carper HT, Barnes RC, Mandell GL.
    Immunopharmacology; 1995 Nov 27; 31(1):19-29. PubMed ID: 8655288
    [Abstract] [Full Text] [Related]

  • 4. Neutrophil A2A adenosine receptor inhibits inflammation in a rat model of meningitis: synergy with the type IV phosphodiesterase inhibitor, rolipram.
    Sullivan GW, Linden J, Buster BL, Scheld WM.
    J Infect Dis; 1999 Nov 27; 180(5):1550-60. PubMed ID: 10515815
    [Abstract] [Full Text] [Related]

  • 5. LPS-stimulated PMN activation and proinflammatory mediator synthesis is downregulated by phosphodiesterase inhibition: role of pentoxifylline.
    Coimbra R, Loomis W, Melbostad H, Tobar M, Porcides RD, Hoyt DB.
    J Trauma; 2004 Dec 27; 57(6):1157-63. PubMed ID: 15625444
    [Abstract] [Full Text] [Related]

  • 6. Enhanced tumor necrosis factor suppression and cyclic adenosine monophosphate accumulation by combination of phosphodiesterase inhibitors and prostanoids.
    Sinha B, Semmler J, Eisenhut T, Eigler A, Endres S.
    Eur J Immunol; 1995 Jan 27; 25(1):147-53. PubMed ID: 7843225
    [Abstract] [Full Text] [Related]

  • 7. Rolipram, a specific type IV phosphodiesterase inhibitor, is a potent inhibitor of HIV-1 replication.
    Angel JB, Saget BM, Walsh SP, Greten TF, Dinarello CA, Skolnik PR, Endres S.
    AIDS; 1995 Oct 27; 9(10):1137-44. PubMed ID: 8519449
    [Abstract] [Full Text] [Related]

  • 8. The effects of cAMP modulation upon the adhesion and respiratory burst activity of immune complex-stimulated equine neutrophils.
    Chilcoat CD, Rowlingson KA, Jones SL.
    Vet Immunol Immunopathol; 2002 Sep 06; 88(1-2):65-77. PubMed ID: 12088646
    [Abstract] [Full Text] [Related]

  • 9. The synergistic effect of adenosine A2A receptors agonist, type IV phosphodiestease inhibitor and ATP-sensitive K channels activation on free radicals production and aggregation of human polymorphoneuclear leukocytes.
    Al-Ayadhi LY, Al-Tuwajri AS.
    Pharmacol Res; 2004 Aug 06; 50(2):157-63. PubMed ID: 15177304
    [Abstract] [Full Text] [Related]

  • 10. Characterization of cAMP-dependent inhibition of LPS-induced TNF alpha production by rolipram, a specific phosphodiesterase IV (PDE IV) inhibitor.
    Prabhakar U, Lipshutz D, Bartus JO, Slivjak MJ, Smith EF, Lee JC, Esser KM.
    Int J Immunopharmacol; 1994 Oct 06; 16(10):805-16. PubMed ID: 7843852
    [Abstract] [Full Text] [Related]

  • 11. Beneficial effects of the phosphodiesterase inhibitors BRL 61063, pentoxifylline, and rolipram in a murine model of endotoxin shock.
    Badger AM, Olivera DL, Esser KM.
    Circ Shock; 1994 Dec 06; 44(4):188-95. PubMed ID: 7628060
    [Abstract] [Full Text] [Related]

  • 12. A peptide of the alpha 3(IV) chain of type IV collagen modulates stimulated neutrophil function via activation of cAMP-dependent protein kinase and Ser/Thr protein phosphatase.
    Fawzi A, Robinet A, Monboisse JC, Ziaie Z, Kefalides NA, Bellon G.
    Cell Signal; 2000 May 06; 12(5):327-35. PubMed ID: 10822174
    [Abstract] [Full Text] [Related]

  • 13. The phosphodiesterase inhibitors pentoxifylline and rolipram prevent diabetes in NOD mice.
    Liang L, Beshay E, Prud'homme GJ.
    Diabetes; 1998 Apr 06; 47(4):570-5. PubMed ID: 9568689
    [Abstract] [Full Text] [Related]

  • 14. Effects of selective phosphodiesterase inhibitors on the polymorphonuclear leukocyte respiratory burst.
    Nielson CP, Vestal RE, Sturm RJ, Heaslip R.
    J Allergy Clin Immunol; 1990 Nov 06; 86(5):801-8. PubMed ID: 1977788
    [Abstract] [Full Text] [Related]

  • 15. Cyclic nucleotide phosphodiesterase type IV participates in the regulation of IL-10 and in the subsequent inhibition of TNF-alpha and IL-6 release by endotoxin-stimulated macrophages.
    Kambayashi T, Jacob CO, Zhou D, Mazurek N, Fong M, Strassmann G.
    J Immunol; 1995 Nov 15; 155(10):4909-16. PubMed ID: 7594495
    [Abstract] [Full Text] [Related]

  • 16. Differential regulation of human monocyte-derived TNF alpha and IL-1 beta by type IV cAMP-phosphodiesterase (cAMP-PDE) inhibitors.
    Verghese MW, McConnell RT, Strickland AB, Gooding RC, Stimpson SA, Yarnall DP, Taylor JD, Furdon PJ.
    J Pharmacol Exp Ther; 1995 Mar 15; 272(3):1313-20. PubMed ID: 7891349
    [Abstract] [Full Text] [Related]

  • 17. Pentoxifylline differentially regulates migration and respiratory burst activity of the neutrophil.
    Dunzendorfer S, Schratzberger P, Reinisch N, Kähler CM, Wiedermann CJ.
    Ann N Y Acad Sci; 1997 Dec 15; 832():330-40. PubMed ID: 9704061
    [Abstract] [Full Text] [Related]

  • 18. Interleukin-10 does not mediate the inhibitory effect of PDE-4 inhibitors and other cAMP-elevating drugs on lipopolysaccharide-induced tumors necrosis factor-alpha generation from human peripheral blood monocytes.
    Seldon PM, Barnes PJ, Giembycz MA.
    Cell Biochem Biophys; 1998 Dec 15; 29(1-2):179-201. PubMed ID: 9631245
    [Abstract] [Full Text] [Related]

  • 19. Regulation of tumour necrosis factor production by adrenal hormones in vivo: insights into the antiinflammatory activity of rolipram.
    Pettipher ER, Labasi JM, Salter ED, Stam EJ, Cheng JB, Griffiths RJ.
    Br J Pharmacol; 1996 Apr 15; 117(7):1530-4. PubMed ID: 8730750
    [Abstract] [Full Text] [Related]

  • 20. The specific type IV phosphodiesterase inhibitor rolipram suppresses tumor necrosis factor-alpha production by human mononuclear cells.
    Semmler J, Wachtel H, Endres S.
    Int J Immunopharmacol; 1993 Apr 15; 15(3):409-13. PubMed ID: 8505151
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.